Skip to main content
Clinical Trials/NCT00289029
NCT00289029
Completed
Phase 4

Visipaque and Isovue in Cardiac Angiography in Renally Impaired Patients

Bracco Diagnostics, Inc1 site in 1 country400 target enrollmentJuly 2005

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
CIN
Sponsor
Bracco Diagnostics, Inc
Enrollment
400
Locations
1
Primary Endpoint
Increase in SCr at 48-72 hours post dose
Status
Completed
Last Updated
19 years ago

Overview

Brief Summary

The main purpose of this study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue or Visipaque in patients with moderate to severe renal insufficiency undergoing cardiac angiography. Serum creatinine will be measured before and up to 48-72 hours after the administration of the contrast agent to evaluate renal function.

Registry
clinicaltrials.gov
Start Date
July 2005
End Date
June 2006
Last Updated
19 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Referred for cardiac angiography; with a documented predose eGFR of greater than or equal to 20 and less than 60 mL/min/1.73m2

Exclusion Criteria

  • Unstable renal function; concurrent administration of nephrotoxic drugs, undergoing dialysis

Outcomes

Primary Outcomes

Increase in SCr at 48-72 hours post dose

Secondary Outcomes

  • Decrease in eGFR at 48-72 hours post dose; occurrence of adverse events; effect on heart rate

Study Sites (1)

Loading locations...

Similar Trials